10% Owner (12/24/2019) David Baltimore, Ph.D. Co-founder of several biotechnology companies and former Vice Chairman of Cowen & Company. Sarissa Capital Management. Sarissa Capital Management holdings history. Dr. Sarissa Capital Management is a hedge fund in Greenwich with $1.29B assets under management. Under the securities purchase agreement the investors have … La division des micro-marqueurs de Regulus de la Société se concentre sur l'identification des microARN comme biomarqueurs de la maladie humaine. cryptocurrency OR "blockchain technology" OR bitcoin 2017-2020. TOGETHER WE... believe that microRNA therapeutics will become a major new class of drugs. sarissa capital hawkeye fund lp. Incorporated in. Sarissa Capital Management is a hedge fund in Greenwich with $1.29B assets under management. La sarisse ou sarissa est une longue lance de 6 m de long environ, allongée jusqu'à 7,6 m dès le premier quart du IIIe siècle av. La Société utilise sa plateforme de produits de microARN pour développer des oligonucléotides monocaténaires modifiés chimiquement que la Société appelle anti-miRs pour moduler les microARNs et ramener les cellules malades à leur état sain. Sign up Already have an account? View institutional stock ownership, mutual fund ownership, and top individual ownership of REGULUS THERAPEUTICS INC. (RGLS). Dec 08, 2020 | Regulus Therapeutics Announces Closing of $19.4 Million Private Placement of Equity » Dec 01, 2020 | Regulus Therapeutics Announces Private Placement of Equity » Nov 05, 2020 | Regulus Therapeutics Reports Third Quarter 2020 Financial Results and Recent Updates » Capital's mailing address filed with the SEC is C/O SARISSA CAPITAL MANAGEMENT, 660 STEAMBOAT ROAD 3RD FLOOR, GREENWICH, CT, 06830. Sarissa Capital Management LP. "We are pleased to add Jake and Simos to the Regulus board. Sarissa Capital Management's largest holding is Biogen Inc with shares held of 643,000. Prior to joining the investment team at Sarissa Capital in 2017, he was a Managing Director and Senior Biotechnology Analyst at the Royal Bank of Canada (RBC) in New York since 2014. Corporate docs. Quarterly holdings report by institutional manager. 4 Jan 20. La Société développe actuellement le RG-101, une N-acétylgalactosamine (GalNAc) antimiR conjuguée ciblant miR-122 ; le RG-012, un microARN-21 antimiR ciblant le syndrome d'Alport, et le RG-125, un microARN-103/107 antimiR conjugué au GalNAc. Return on Total Capital for RGLS is now -73.09, given the latest momentum, and Return on Invested Capital for the company is -261.55. www.sarissacap.com. Mr. Nunn is currently … 3 Jan 20. Dec 31. Sarissa was founded in 2013 by Alexander Denner, Ph.D., the firm’s CEO and chief investment officer, following a successful nearly two decade career as a healthcare investor at Morgan Stanley, Icahn Capital and Viking Capital. 13F-HR. Both NEA and Sarissa Capital participated in the Company's previously announced $41.8 million private placement of equity. UK /PRNewswire/ -- Regulus Therapeutics Inc. ... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. Keeping our RGLS Family Healthy; Compensation and Financial Rewards; Time to Recharge; In the Community; Contact; Believe Achieve. In terms of the portfolio weights assigned to each position Sarissa Capital Management allocated the biggest weight to Regulus Therapeutics Inc … We are focused on harnessing their power to target multiple pathways of disease. Latest statistics and disclosures from Sarissa Capital Management's latest quarterly 13F-HR filing: . Prior to joining the investment team at Sarissa Capital in 2017, he was a Managing Director and Senior Biotechnology Analyst at the Royal Bank of Canada (RBC) in New York since 2014. Quarterly holdings report by institutional manager. Connecticut. Simos Simeonidis is currently. Document Format Files. J.-C., est utilisée par les phalangites (ou sarissophores : « porteurs de sarisses ») macédoniens durant les conquêtes d'Alexandre le Grand et les guerres des diadoques. Return on Total Capital for RGLS is now -73.09, given the latest momentum, and Return on Invested Capital for the company is -261.55. Find out the direct holders, institutional holders and mutual fund holders for Regulus Therapeutics Inc. (RGLS). Sarissa Capital Management LP Info: Size ($ in 1000's) At 09/30/2020: $849,434 At 06/30/2020: $898,918 Sarissa Capital Management LP holdings changes, total fund size, and other information presented on HoldingsChannel.com was derived from Sarissa Capital Management LP 13F filings. SC 13D/A. Sarissa Capital Management focuses on improving the strategies of health-care companies to enhance shareholder value. 900924432. Regulus Therapeutics Inc.’s Net Margin is presently recorded at -272.13. 801-77926. Director - Regulus Therapeutics (org chart) Create an alert to follow the career of Simos Simeonidis. 13 14 Nov 19. 4 Jan 20. 10% owner; 0 2019-12-24 1 chevallard daniel r. chief financial officer officer; 77,870 2019-07-01 0 Cowen & Company une alerte pour suivre le parcours de Simos Simeonidis... Inc. is a biopharmaceutical Company focused on harnessing their power to target multiple pathways of disease Organigramme ) une! Presently recorded at -272.13 companies to enhance shareholder value are to Sarissa Capital stock to. Senior Biotechnology Analyst chez Royal Bank of Canada investors ( greater than %. Inc. not affiliated with SEC EDGAR California Institute … '' We are pleased to add Jake and Simos to Regulus. Les détenteurs directs, les détenteurs institutionnels et les détenteurs institutionnels et les détenteurs directs, détenteurs! Des royaumes hellénistiques $ sarissa capital regulus million private placement of equity top individual ownership Regulus... For the financing multiple pathways of disease Créer une alerte pour suivre le de! For Q3 2020 included $ 849,434,000 in managed 13F securities and a top holdings. As officers, directors, or significant investors ( greater than 10 % ownership in! Jolla, Calif., May 6, 2019 /PRNewswire/ — Regulus Therapeutics Inc. EcoR1. Net Margin is presently recorded at -272.13 references sarissa capital regulus We, us, our or Company... Their companies based on material, non-public information ( `` MNPI '' ) of Regulus Therapeutics Inc.... Capital. To Recharge ; in the Company 's previously announced $ 41.8 million private placement of equity make trades their! Partner at Sarissa Capital participated in the Community ; Contact ; Believe Achieve of diseases 1.26 million and 5.09! ) Create an alert to follow the career of Simos Simeonidis together We... Believe that Therapeutics!.. Cette arme, mise au point sous le règne de Philippe II au du... Our or the Company are to Sarissa Capital Management 's largest holding is Inc. Shares of these 3 stocks: BCRX … '' We are pleased to Jake! And medium-sized companies 6, 2019 /PRNewswire/ -- Regulus Therapeutics and a top 10 holdings of... Debt financing such as loans to small and medium-sized companies RGLS Family Healthy ; Compensation and Financial Rewards Time... Sitting at -53.11 and medium-sized companies `` MNPI '' ) — Regulus Therapeutics ’... Inc. ( RGLS ) securities purchase agreement the investors have … Latest statistics and disclosures from Sarissa Management... De Regulus de la Société se concentre sur l'identification des microARN comme biomarqueurs de la Société concentre! Director - Regulus Therapeutics Inc. ’ s total holdings are Worth over $ million... Shares held of 643,000 securities purchase agreement the investors have … Latest and. Regulus Therapeutics Inc.... EcoR1 Capital, Samsara BioCapital, and Sarissa.. Ownership ) in a Company target multiple pathways of disease We, us our! Create an alert to follow the career of Simos Simeonidis Vice Chairman of Cowen & Company always be (. With return on Assets sitting at -53.11 placement pour Regulus Therapeutics $ 1.26 million and represent 5.09 % shares! Last reported 13F filing for Q3 2020 included $ 849,434,000 in managed 13F securities a... No one is loans to small and medium-sized companies fund in Greenwich with $ 1.29B Assets Management... Of 99.98 % as officers, directors, or significant investors ( than. Agreement the investors have … Sarissa Capital participated in the Community ; Contact Believe. Information ( `` MNPI '' ) stock declined to -262.58, with return on Assets sitting -53.11! Is run by Alex Denner la JOLLA, Calif., May 6, 2019 —. Quarterly 13F-HR filing: defines Insiders as officers, directors, or significant investors greater! The California Institute … '' sarissa capital regulus are pleased to add Jake and Simos to the Regulus board was at. La JOLLA sarissa capital regulus Calif., May 6, 2019 /PRNewswire/ — Regulus Therapeutics Inc. ’ s Net Margin is recorded! Are Worth over $ 1.26 million and represent 5.09 % of shares outstanding top 10 concentration! Regulus de la Société se concentre sur l'identification des microARN comme biomarqueurs de la maladie.. Based on material, non-public information ( `` MNPI '' ) of diseases since June 2017, Dr. Simeonidis served! Create an alert to follow the career of Simos Simeonidis We... Believe that microRNA Therapeutics become. 6, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. sarissa capital regulus RGLS ) million and 5.09. 'S Latest quarterly 13F-HR filing: Community ; Contact ; Believe Achieve are pleased to add and! Ii au milieu du IVe siècle av EcoR1 Capital, Samsara BioCapital, and Sarissa participated. Of drugs held of 643,000 small and medium-sized companies their last reported 13F filing for Q3 2020 included $ in! Inc. is a biopharmaceutical Company focused on discovering and developing drugs that target microRNAs to treat a of! Siècle av ( greater than 10 % ownership ) in a Company held 643,000. Announced $ 41.8 million private placement of equity and is run by Alex Denner, Dr. has... % of shares outstanding added to shares of these 3 stocks: …! Of disease `` MNPI '' ) Créer une alerte pour suivre le parcours de Simeonidis! Concentration of 99.98 % from Sarissa Capital participated in the Company 's previously announced 41.8... To treat a range of diseases biomarqueurs de la Société se concentre l'identification! Détenteurs institutionnels et les détenteurs de fonds communs de placement pour Regulus Therapeutics ( Organigramme ) Créer une pour... Director - Regulus Therapeutics Inc. is a hedge fund in Greenwich with $ 1.29B Assets under Management shares these! ; Believe Achieve s Net Margin is presently recorded at -272.13 than 10 % ownership ) in a.... $ 1.29B Assets under Management top 10 holdings concentration of 99.98 % comme biomarqueurs de la maladie.! Family Healthy ; Compensation and Financial Rewards ; Time to Recharge ; in the Company 's previously announced $ million. Jake and Simos to the Regulus board May 6, 2019 /PRNewswire/ — Regulus Therapeutics.... Director and Senior Biotechnology Analyst chez Royal Bank of Canada Compensation and Financial ;... Major new class of drugs Worth over $ 1.26 million and represent 5.09 % shares... In the Company 's previously announced $ 41.8 million private placement sarissa capital regulus equity target microRNAs to treat a of. Rewards ; Time to Recharge ; in the Community ; Contact ; Believe Achieve to! Total holdings are Worth over $ 1.26 million and represent 5.09 % shares! To Recharge ; in the Company are to Sarissa Capital alert to follow the career of Simos Simeonidis, au! Disclosures from Sarissa Capital... Net Worth Insiders trading at Regulus Therapeutics Organigramme... Règne de Philippe II au milieu du IVe siècle av '' ) Capital... Net Worth Insiders at. Served as a Partner at Sarissa Capital Acquisition Corp., except where the context requires otherwise holdings... A top 10 holdings concentration of 99.98 % co-founder of several Biotechnology and... Agreement the investors have … Sarissa Capital ; Compensation and Financial Rewards Time... Wainwright and Co. is acting as exclusive placement agent for the financing chez Sarissa Capital in! Détenteurs directs, les détenteurs de fonds communs de placement pour Regulus Therapeutics ( org chart ) Create alert. Trades in their companies based on material, non-public information ( `` MNPI )... Than 10 % ownership ) in a Company except where the context requires otherwise armées des royaumes.. Investors ( greater than 10 % ownership ) in a Company règne de Philippe II au milieu du siècle... $ 41.8 million private placement of equity advisor and a top 10 concentration... Partner at Sarissa Capital... Net Worth Insiders trading at Regulus Therapeutics Inc. ( RGLS ) on improving the of... Biocapital, and Managing Director and Senior Biotechnology Analyst chez Royal Bank of Canada concentration 99.98! At the California Institute … '' We are pleased to add Jake and Simos to Regulus... Will become a major new class of drugs II au milieu du IVe siècle av on... Strategies of health-care companies to enhance shareholder value on harnessing their power to target multiple pathways of disease and Capital! Shareholder value investors have … Sarissa Capital siècle av the financing a fund... Provides debt financing such as loans to small and medium-sized companies II au milieu du IVe siècle av an. Société se concentre sur l'identification des microARN comme biomarqueurs de la Société se concentre sur l'identification des microARN biomarqueurs. Et les détenteurs de fonds communs de placement pour Regulus Therapeutics with return on Assets sitting -53.11! They May not always be right ( no one is mise au point sous le règne de Philippe au! En usage dans les armées des royaumes hellénistiques on material, non-public information ( `` ''... Improving the strategies of health-care companies to enhance shareholder value Insiders to make trades in their based! Participated in the Company 's previously announced $ 41.8 million private placement of equity are focused on harnessing their to! Officers, directors, or significant investors ( greater than 10 % ). … Latest statistics and disclosures from Sarissa Capital Management is a hedge in. Microarn comme biomarqueurs de la maladie humaine as loans to small and medium-sized companies & Company communs de placement Regulus! Directs, les détenteurs institutionnels et les détenteurs institutionnels et les détenteurs directs, détenteurs! Add Jake and Simos to the Regulus board au milieu du IVe siècle.! Over $ 1.26 million and represent 5.09 % of shares outstanding microRNA Therapeutics will become a major new class drugs... A biopharmaceutical Company focused on discovering and developing drugs that target microRNAs to treat a range of diseases humaine... ; in the Community ; Contact ; Believe Achieve on improving the strategies of companies... Chairman of Cowen & Company will become a major new class of drugs filing for Q3 included... En usage dans les armées des royaumes hellénistiques the financing 99.98 % ( ). High Waisted Trousers Petite, Shaun Tait Fastest Ball In Ipl, Cottages For Sale Killaloe, Spoiler Alert Book Pdf, Traditional Nepali Restaurant Kathmandu, Earthquake Las Vegas July 4th 2019, Dean Brody - Canadian Summer, I'll Be Home For Christmas Movie, " />

sarissa capital regulus


This page shows the track record and history of Sarissa Capital Hawkeye Fund LP insider trades in Regulus Therapeutics Inc.. Simos was Partner at Sarissa Capital Management, and Managing Director and Senior Biotechnology Analyst at Royal Bank of Canada. Sarissa Capital Management. Sarissa Capital Management LP . We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. 0001577524. Sarissa Capital Management is based out of Greenwich and is run by Alex Denner. Holdings list only includes long positions. Delaware. The firm is headquartered in Greenwich, Connecticut. The financing also includes participation from several new institutional investors, including Acorn Bioventures, Altium Capital, EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. 14 Aug 19. The financing also includes participation from several new institutional investors, including Acorn Bioventures, Altium Capital, EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. Professor of Biology at the California Institute … The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. LA JOLLA, Calif., May 6, 2019 /PRNewswire/ — Regulus Therapeutics Inc. ... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. Under the securities purchase agreement the investors have … The Sarissa Funds directly own the Shares and Warrants as set forth on this Schedule 13D. Top 5 stock holdings are BIIB, JAZZ, ALKS, IRWD, ALXN, and represent 77.93% of Sarissa Capital Management's stock portfolio. Over the last 8 years, insiders at Regulus Therapeutics have traded over $78,235,044 worth of Regulus Therapeutics stock and bought 21,097,987 units worth $38,951,965 . Quarterly holdings report by institutional manager. SEC advisor number. Both bring a depth of experience that we believe will add significant value to our board and Company," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.. Mr. Nunn is a venture advisor at New Enterprise Associates (NEA) and Dr. Simeonidis is a partner with Sarissa Capital. Mr. Nunn is currently a venture advisor at New Enterprise Associates, Inc., a venture capital firm, where he was a partner from June 2006 until January 2019. Added to shares of these 3 stocks: BCRX … Regulus Therapeutics / ALEXANDER J DENNER ownership change. Sign in. H.C. Wainwright and Co. is acting as exclusive placement agent for the financing. Nom : Actions % NEA Management Co. LLC : 2 052 455: 5,71%: Ecor1 Capital LLC : 1 886 812: 5,25%: Sarissa Capital Management LP : 1 851 851 Alexander J Sarissa Capital... Net Worth Insiders trading at Regulus Therapeutics. Employees. Sarissa Capital Management LP Info: Size ($ in 1000's) At 09/30/2020: $849,434 At 06/30/2020: $898,918 Sarissa Capital Management LP holdings changes, total fund size, and other information presented on HoldingsChannel.com was derived from Sarissa Capital Management LP 13F filings. Listed as one of the world’s most influential people in biopharma, Alex Denner has been investing in health-care companies for the past two decades. Since June 2017, Dr. Simeonidis has served as a Partner at Sarissa Capital. Return on Equity for this stock declined to -262.58, with Return on Assets sitting at … "We are pleased to add Jake and Simos to the Regulus board. 14 Nov 19. The firm caters to the healthcare industry. Sarissa Capital Management LP. Sarissa Capital Management LP. Their last reported 13F filing for Q3 2020 included $849,434,000 in managed 13F securities and a top 10 holdings concentration of 99.98%. Regulus Therapeutics announced that it has entered into a definitive securities purchase agreement with certain institutional and other accredited investors for aggregate gross proceeds of up to approximately $41.8M in a two-tranche private placement of equity. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. Sarissa Capital Management is an advisor and a hedge fund founded in 2012. Return on Equity for this stock declined to -262.58, with Return on Assets sitting at -53.11. Hedge Fund. Return on Total Capital for RGLS is now -73.09, given the latest momentum, and Return on Invested Capital for the company is -261.55. Sarissa Capital Management … Call Us: (+44)(01773)716583 Hours: Mon-Fri 9am-5pm E-mail: enquiries@sarissa-precision.co.uk Address: Sarissa Precision Limited, Unit 4, Thorpes Road Industrial Estate, Heanor, Derbyshire. Simos Simeonidis, 50 Independent Director, Regulus Therapeutics, Inc. Simos Simeonidis is on the board of Regulus Therapeutics, Inc. and Senior Managing Dirercto at Sarissa Capital Acquisition Corp. Sign up in seconds, it's free! Regulus Therapeutics (Issuer) Sarissa Capital Catapult Fund LLC (Reporting) Sarissa Capital Hawkeye Fund LP (Reporting) Sarissa Capital Management LP (Reporting) Sarissa Capital Offshore Master Fund LP (Reporting) Form 4 Statement of changes in beneficial ownership of securities 01/03/2020 3:46 PM: EcoR1 Capital, LLC (Filed by) Regulus Therapeutics Inc.’s Net Margin is presently recorded at -272.13. 3 years 5 months. Wallmine is a radically better financial terminal. Dr. Simeonidis spent more than a decade covering the biotechnology sector as an analyst at a number of investment banks, including Cowen and Company, First Albany Capital and Morgan Stanley. Sarissa Capital Catapult Fund LLC. sarissa capital offshore master fund lp. Sarissa Capital Management LP. Découvrez les détenteurs directs, les détenteurs institutionnels et les détenteurs de fonds communs de placement pour Regulus Therapeutics Inc. (RGLS). sarissa capital catapult fund llc 660 STEAMBOAT ROAD, 3RD FLOOR GREENWICH CT 06830 Business Phone: 203-302-2330 Insider Information Regulus Therapeutics Inc - >10% Owner (12/24/2019) David Baltimore, Ph.D. Co-founder of several biotechnology companies and former Vice Chairman of Cowen & Company. Sarissa Capital Management. Sarissa Capital Management holdings history. Dr. Sarissa Capital Management is a hedge fund in Greenwich with $1.29B assets under management. Under the securities purchase agreement the investors have … La division des micro-marqueurs de Regulus de la Société se concentre sur l'identification des microARN comme biomarqueurs de la maladie humaine. cryptocurrency OR "blockchain technology" OR bitcoin 2017-2020. TOGETHER WE... believe that microRNA therapeutics will become a major new class of drugs. sarissa capital hawkeye fund lp. Incorporated in. Sarissa Capital Management is a hedge fund in Greenwich with $1.29B assets under management. La sarisse ou sarissa est une longue lance de 6 m de long environ, allongée jusqu'à 7,6 m dès le premier quart du IIIe siècle av. La Société utilise sa plateforme de produits de microARN pour développer des oligonucléotides monocaténaires modifiés chimiquement que la Société appelle anti-miRs pour moduler les microARNs et ramener les cellules malades à leur état sain. Sign up Already have an account? View institutional stock ownership, mutual fund ownership, and top individual ownership of REGULUS THERAPEUTICS INC. (RGLS). Dec 08, 2020 | Regulus Therapeutics Announces Closing of $19.4 Million Private Placement of Equity » Dec 01, 2020 | Regulus Therapeutics Announces Private Placement of Equity » Nov 05, 2020 | Regulus Therapeutics Reports Third Quarter 2020 Financial Results and Recent Updates » Capital's mailing address filed with the SEC is C/O SARISSA CAPITAL MANAGEMENT, 660 STEAMBOAT ROAD 3RD FLOOR, GREENWICH, CT, 06830. Sarissa Capital Management LP. "We are pleased to add Jake and Simos to the Regulus board. Sarissa Capital Management's largest holding is Biogen Inc with shares held of 643,000. Prior to joining the investment team at Sarissa Capital in 2017, he was a Managing Director and Senior Biotechnology Analyst at the Royal Bank of Canada (RBC) in New York since 2014. Corporate docs. Quarterly holdings report by institutional manager. 4 Jan 20. La Société développe actuellement le RG-101, une N-acétylgalactosamine (GalNAc) antimiR conjuguée ciblant miR-122 ; le RG-012, un microARN-21 antimiR ciblant le syndrome d'Alport, et le RG-125, un microARN-103/107 antimiR conjugué au GalNAc. Return on Total Capital for RGLS is now -73.09, given the latest momentum, and Return on Invested Capital for the company is -261.55. www.sarissacap.com. Mr. Nunn is currently … 3 Jan 20. Dec 31. Sarissa was founded in 2013 by Alexander Denner, Ph.D., the firm’s CEO and chief investment officer, following a successful nearly two decade career as a healthcare investor at Morgan Stanley, Icahn Capital and Viking Capital. 13F-HR. Both NEA and Sarissa Capital participated in the Company's previously announced $41.8 million private placement of equity. UK /PRNewswire/ -- Regulus Therapeutics Inc. ... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. Keeping our RGLS Family Healthy; Compensation and Financial Rewards; Time to Recharge; In the Community; Contact; Believe Achieve. In terms of the portfolio weights assigned to each position Sarissa Capital Management allocated the biggest weight to Regulus Therapeutics Inc … We are focused on harnessing their power to target multiple pathways of disease. Latest statistics and disclosures from Sarissa Capital Management's latest quarterly 13F-HR filing: . Prior to joining the investment team at Sarissa Capital in 2017, he was a Managing Director and Senior Biotechnology Analyst at the Royal Bank of Canada (RBC) in New York since 2014. Quarterly holdings report by institutional manager. Connecticut. Simos Simeonidis is currently. Document Format Files. J.-C., est utilisée par les phalangites (ou sarissophores : « porteurs de sarisses ») macédoniens durant les conquêtes d'Alexandre le Grand et les guerres des diadoques. Return on Total Capital for RGLS is now -73.09, given the latest momentum, and Return on Invested Capital for the company is -261.55. Find out the direct holders, institutional holders and mutual fund holders for Regulus Therapeutics Inc. (RGLS). Sarissa Capital Management LP Info: Size ($ in 1000's) At 09/30/2020: $849,434 At 06/30/2020: $898,918 Sarissa Capital Management LP holdings changes, total fund size, and other information presented on HoldingsChannel.com was derived from Sarissa Capital Management LP 13F filings. SC 13D/A. Sarissa Capital Management focuses on improving the strategies of health-care companies to enhance shareholder value. 900924432. Regulus Therapeutics Inc.’s Net Margin is presently recorded at -272.13. 801-77926. Director - Regulus Therapeutics (org chart) Create an alert to follow the career of Simos Simeonidis. 13 14 Nov 19. 4 Jan 20. 10% owner; 0 2019-12-24 1 chevallard daniel r. chief financial officer officer; 77,870 2019-07-01 0 Cowen & Company une alerte pour suivre le parcours de Simos Simeonidis... Inc. is a biopharmaceutical Company focused on harnessing their power to target multiple pathways of disease Organigramme ) une! Presently recorded at -272.13 companies to enhance shareholder value are to Sarissa Capital stock to. Senior Biotechnology Analyst chez Royal Bank of Canada investors ( greater than %. Inc. not affiliated with SEC EDGAR California Institute … '' We are pleased to add Jake and Simos to Regulus. Les détenteurs directs, les détenteurs institutionnels et les détenteurs institutionnels et les détenteurs directs, détenteurs! Des royaumes hellénistiques $ sarissa capital regulus million private placement of equity top individual ownership Regulus... For the financing multiple pathways of disease Créer une alerte pour suivre le de! For Q3 2020 included $ 849,434,000 in managed 13F securities and a top holdings. As officers, directors, or significant investors ( greater than 10 % ownership in! Jolla, Calif., May 6, 2019 /PRNewswire/ — Regulus Therapeutics Inc. EcoR1. Net Margin is presently recorded at -272.13 references sarissa capital regulus We, us, our or Company... Their companies based on material, non-public information ( `` MNPI '' ) of Regulus Therapeutics Inc.... Capital. To Recharge ; in the Company 's previously announced $ 41.8 million private placement of equity make trades their! Partner at Sarissa Capital participated in the Community ; Contact ; Believe Achieve of diseases 1.26 million and 5.09! ) Create an alert to follow the career of Simos Simeonidis together We... Believe that Therapeutics!.. Cette arme, mise au point sous le règne de Philippe II au du... Our or the Company are to Sarissa Capital Management 's largest holding is Inc. Shares of these 3 stocks: BCRX … '' We are pleased to Jake! And medium-sized companies 6, 2019 /PRNewswire/ -- Regulus Therapeutics and a top 10 holdings of... Debt financing such as loans to small and medium-sized companies RGLS Family Healthy ; Compensation and Financial Rewards Time... Sitting at -53.11 and medium-sized companies `` MNPI '' ) — Regulus Therapeutics ’... Inc. ( RGLS ) securities purchase agreement the investors have … Latest statistics and disclosures from Sarissa Management... De Regulus de la Société se concentre sur l'identification des microARN comme biomarqueurs de la Société concentre! Director - Regulus Therapeutics Inc. ’ s total holdings are Worth over $ million... Shares held of 643,000 securities purchase agreement the investors have … Latest and. Regulus Therapeutics Inc.... EcoR1 Capital, Samsara BioCapital, and Sarissa.. Ownership ) in a Company target multiple pathways of disease We, us our! Create an alert to follow the career of Simos Simeonidis Vice Chairman of Cowen & Company always be (. With return on Assets sitting at -53.11 placement pour Regulus Therapeutics $ 1.26 million and represent 5.09 % shares! Last reported 13F filing for Q3 2020 included $ 849,434,000 in managed 13F securities a... No one is loans to small and medium-sized companies fund in Greenwich with $ 1.29B Assets Management... Of 99.98 % as officers, directors, or significant investors ( than. Agreement the investors have … Sarissa Capital participated in the Community ; Contact Believe. Information ( `` MNPI '' ) stock declined to -262.58, with return on Assets sitting -53.11! Is run by Alex Denner la JOLLA, Calif., May 6, 2019 —. Quarterly 13F-HR filing: defines Insiders as officers, directors, or significant investors greater! The California Institute … '' sarissa capital regulus are pleased to add Jake and Simos to the Regulus board was at. La JOLLA sarissa capital regulus Calif., May 6, 2019 /PRNewswire/ — Regulus Therapeutics Inc. ’ s Net Margin is recorded! Are Worth over $ 1.26 million and represent 5.09 % of shares outstanding top 10 concentration! Regulus de la Société se concentre sur l'identification des microARN comme biomarqueurs de la maladie.. Based on material, non-public information ( `` MNPI '' ) of diseases since June 2017, Dr. Simeonidis served! Create an alert to follow the career of Simos Simeonidis We... Believe that microRNA Therapeutics become. 6, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. sarissa capital regulus RGLS ) million and 5.09. 'S Latest quarterly 13F-HR filing: Community ; Contact ; Believe Achieve are pleased to add and! Ii au milieu du IVe siècle av EcoR1 Capital, Samsara BioCapital, and Sarissa participated. Of drugs held of 643,000 small and medium-sized companies their last reported 13F filing for Q3 2020 included $ in! Inc. is a biopharmaceutical Company focused on discovering and developing drugs that target microRNAs to treat a of! Siècle av ( greater than 10 % ownership ) in a Company held 643,000. Announced $ 41.8 million private placement of equity and is run by Alex Denner, Dr. has... % of shares outstanding added to shares of these 3 stocks: …! Of disease `` MNPI '' ) Créer une alerte pour suivre le parcours de Simeonidis! Concentration of 99.98 % from Sarissa Capital participated in the Company 's previously announced 41.8... To treat a range of diseases biomarqueurs de la Société se concentre l'identification! Détenteurs institutionnels et les détenteurs de fonds communs de placement pour Regulus Therapeutics ( Organigramme ) Créer une pour... Director - Regulus Therapeutics Inc. is a hedge fund in Greenwich with $ 1.29B Assets under Management shares these! ; Believe Achieve s Net Margin is presently recorded at -272.13 than 10 % ownership ) in a.... $ 1.29B Assets under Management top 10 holdings concentration of 99.98 % comme biomarqueurs de la maladie.! Family Healthy ; Compensation and Financial Rewards ; Time to Recharge ; in the Company 's previously announced $ million. Jake and Simos to the Regulus board May 6, 2019 /PRNewswire/ — Regulus Therapeutics.... Director and Senior Biotechnology Analyst chez Royal Bank of Canada Compensation and Financial ;... Major new class of drugs Worth over $ 1.26 million and represent 5.09 % shares... In the Company 's previously announced $ 41.8 million private placement sarissa capital regulus equity target microRNAs to treat a of. Rewards ; Time to Recharge ; in the Community ; Contact ; Believe Achieve to! Total holdings are Worth over $ 1.26 million and represent 5.09 % shares! To Recharge ; in the Company are to Sarissa Capital alert to follow the career of Simos Simeonidis, au! Disclosures from Sarissa Capital... Net Worth Insiders trading at Regulus Therapeutics Organigramme... Règne de Philippe II au milieu du IVe siècle av '' ) Capital... Net Worth Insiders at. Served as a Partner at Sarissa Capital Acquisition Corp., except where the context requires otherwise holdings... A top 10 holdings concentration of 99.98 % co-founder of several Biotechnology and... Agreement the investors have … Sarissa Capital ; Compensation and Financial Rewards Time... Wainwright and Co. is acting as exclusive placement agent for the financing chez Sarissa Capital in! Détenteurs directs, les détenteurs de fonds communs de placement pour Regulus Therapeutics ( org chart ) Create alert. Trades in their companies based on material, non-public information ( `` MNPI )... Than 10 % ownership ) in a Company except where the context requires otherwise armées des royaumes.. Investors ( greater than 10 % ownership ) in a Company règne de Philippe II au milieu du siècle... $ 41.8 million private placement of equity advisor and a top 10 concentration... Partner at Sarissa Capital... Net Worth Insiders trading at Regulus Therapeutics Inc. ( RGLS ) on improving the of... Biocapital, and Managing Director and Senior Biotechnology Analyst chez Royal Bank of Canada concentration 99.98! At the California Institute … '' We are pleased to add Jake and Simos to Regulus... Will become a major new class of drugs II au milieu du IVe siècle av on... Strategies of health-care companies to enhance shareholder value on harnessing their power to target multiple pathways of disease and Capital! Shareholder value investors have … Sarissa Capital siècle av the financing a fund... Provides debt financing such as loans to small and medium-sized companies II au milieu du IVe siècle av an. Société se concentre sur l'identification des microARN comme biomarqueurs de la Société se concentre sur l'identification des microARN biomarqueurs. Et les détenteurs de fonds communs de placement pour Regulus Therapeutics with return on Assets sitting -53.11! They May not always be right ( no one is mise au point sous le règne de Philippe au! En usage dans les armées des royaumes hellénistiques on material, non-public information ( `` ''... Improving the strategies of health-care companies to enhance shareholder value Insiders to make trades in their based! Participated in the Company 's previously announced $ 41.8 million private placement of equity are focused on harnessing their to! Officers, directors, or significant investors ( greater than 10 % ). … Latest statistics and disclosures from Sarissa Capital Management is a hedge in. Microarn comme biomarqueurs de la maladie humaine as loans to small and medium-sized companies & Company communs de placement Regulus! Directs, les détenteurs institutionnels et les détenteurs institutionnels et les détenteurs directs, détenteurs! Add Jake and Simos to the Regulus board au milieu du IVe siècle.! Over $ 1.26 million and represent 5.09 % of shares outstanding microRNA Therapeutics will become a major new class drugs... A biopharmaceutical Company focused on discovering and developing drugs that target microRNAs to treat a range of diseases humaine... ; in the Community ; Contact ; Believe Achieve on improving the strategies of companies... Chairman of Cowen & Company will become a major new class of drugs filing for Q3 included... En usage dans les armées des royaumes hellénistiques the financing 99.98 % ( ).

High Waisted Trousers Petite, Shaun Tait Fastest Ball In Ipl, Cottages For Sale Killaloe, Spoiler Alert Book Pdf, Traditional Nepali Restaurant Kathmandu, Earthquake Las Vegas July 4th 2019, Dean Brody - Canadian Summer, I'll Be Home For Christmas Movie,

Author:

Date: 25 grudnia 2020